PT-141 Dosage Chart: 500mcg On-Demand Protocol

PT-141 (bremelanotide) is a cyclic melanocortin receptor agonist that works centrally in the brain to enhance sexual desire and arousal. Unlike PDE5 inhibitors that work peripherally on blood flow, PT-141 targets the melanocortin system in the hypothalamus.

Research-context information only. PT-141 is the active ingredient in an FDA-approved product for women's hypoactive sexual desire disorder; off-label and research-peptide forms for other uses are not FDA-approved. Protocols, doses, and reactions reported below come from published clinical trials and self-reported community sources. This article reports what has been documented, not what should be done. Consult a licensed physician for personal medical decisions.

PT-141 is FDA-approved for women with HSDD at 1.75 mg. Community protocols use lower doses (500 mcg) to balance efficacy with tolerability. This is not medical advice.

Quick Reference: Standard Protocol

Cycling Details

PT-141 is an on-demand medication — no loading phase, no fixed cycling. Use as needed, maximum once per 24 hours.

First-time use: Community protocols describe a 500 mcg starting dose to assess tolerability. Nausea is commonly reported on initial doses but typically decreases with repeated use.

Tolerance management: Some users report decreased effectiveness with frequent use. Taking 1-2 weeks off every month may help maintain sensitivity.

Timing optimization: Effects begin 15-30 minutes post-injection and peak at 1-2 hours. Community sources describe injecting 30 minutes before anticipated activity.

Routes of Administration

Subcutaneous injection is the only practical route. Clinical trials and the FDA-approved formulation both use SC injection.

• Injection sites: Abdomen, thigh, upper arm — anywhere with subcutaneous fat
• Volume: 0.1 mL with an insulin syringe (29-31 gauge)
• Not oral: PT-141 is a cyclic peptide degraded by stomach acid
• Not nasal: Early research explored nasal delivery, but SC proved more reliable

Reconstitution Quick Reference

Math: 10 mg / 2 mL = 5 mg/mL = 5,000 mcg/mL. For 500 mcg: 500 / 5,000 = 0.1 mL = 10 units.

Community protocols describe gentle swirling — not shaking — to avoid degrading the peptide, with storage at 2–8°C and use within 28 days.

Affiliate disclosure: vendor links in this article are affiliate links — The Peptide Catalog may earn a commission if you buy through them, at no additional cost to you.

Where These Numbers Come From

Community PT-141 protocols are informed by extensive clinical trial data, including the FDA-approved regimen.

FDA-approved dose: 1.75 mg SC for HSDD in premenopausal women. The RECONNECT Phase III trials in 1,267 women showed significant improvement in sexual desire and distress reduction (Kingsberg et al., 2019).

Male studies: Doses of 7-20 mg showed efficacy in men with ED, though with higher nausea rates. Lower doses (1-2 mg) showed particular promise for psychogenic ED (Wessells et al., 2000).

Why community doses are lower: 500 mcg-1 mg balances efficacy against nausea (which increases substantially at higher doses). Individual variation means some achieve desired effects well below the FDA dose. Male users may need slightly lower doses than the female FDA protocol.

Stacking Protocols

Protocols above are drawn from documented community stacking reports, not prescriptive recommendations.

Documented protocols introduce compounds separately to assess individual response. Nausea from PT-141 may be amplified by other compounds.

Side Effects & Safety

• Nausea — 40%+ in clinical trials, most common side effect, usually mild-moderate
• Flushing — facial warmth and redness, typically brief
• Headache — usually mild, resolves within hours
• Injection site reactions — redness, minor swelling
• Fatigue and dizziness — less common
• Max frequency: Once per 24 hours — more frequent dosing increases nausea without additional benefit
• Pregnancy: Contraindicated (category X)
• Nausea management: Community sources describe a 500 mcg starting dose taken with light food; ginger supplements are reported to help, and tolerance develops with repeated use

mg to Units Conversion

On a standard 100-unit insulin syringe, each "unit" equals 0.01 mL (so 100 units = 1 mL). Once PT-141 is reconstituted, the conversion from a target dose to syringe units depends on the chosen dilution.

The two reconstitution ratios most often described in community protocols are below.

Reconstitution A: 10 mg vial + 2 mL BAC water (5 mg/mL) — the standard dilution from the Quick Reference above.

Reconstitution B: 10 mg vial + 3 mL BAC water (3.33 mg/mL) — more BAC water for larger, easier-to-measure draws.

These conversions reflect the dilutions documented in community reconstitution protocols. They report how the math is described, not a recommended dosing schedule.